Короткий опис (реферат):
They have learnt the efficiency and safety of long-term use of fenspiride in 27 geriartric patients with COPD. The patients under study had infection exacerbation of COPD and received antimicrobial, bronchodilating therapy. The therapy of fenspiride was performed during 14 days in the daily dose of 240 mg up to 3 months in the daily dose of 160 mg. After the end of the research the significant improvement in the clinical parameters and stabilization in the functional parameters have been observed. Side effects of fenspiride (xerostomia, dyspepsia, sleepiness) were observed in 7 (22,2%) patients and did not regguire the drug cancellation. None of the patients had the comorbide diseases exacerbation.
